The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Email correspondence between Commissioner Ramirez and Google between July 1, 2012 and January 31, 2013
Email correspondence between Commissioner Ramirez and Google between July 1, 2012 and January 31, 2013
Response to Requester (no documents) - Email correspondence between Commissioner Ramirez and the White House between July 1, 2012 and January 31, 2013
20150701: Group 1 Automotive, Inc.; Irvin David Irrevocable Trust
20150718: Visa Inc.; TrialPay, Inc.
20150719: Genstar Capital Partners VI, L.P.; Snow Phipps II, L.P.
20150720: Hebei Iron & Steel Group, Co. Ltd.; Bruno Bolfo
20150723: Sudesh Arora; Affinity Acquisition Holdings Corp.
20150725: Sola Ltd, Charitable Trust; TerreStar Corporation
20150744: Pershing Square Holdings, Ltd.; Valeant Pharmaceuticals International, Inc.
20150745: Pershing Square, L.P.; Valeant Pharmaceuticals International, Inc.
20150746: Pershing Square International, Ltd.; Valeant Pharmaceuticals International, Inc.
Sun Pharmaceutical Industries, Ltd., et al., In the Matter of
Pharmaceutical companies Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd. agreed to divest Ranbaxy’s interests in generic minocycline tablets in order to settle FTC charges that Sun’s $4 billion proposed acquisition of Ranbaxy would likely be anticompetitive. Torrent Pharmaceuticals Ltd., a global drug company based in India that markets generic drugs in the United States, will acquire the divested assets. Under the settlement, Sun and Ranbaxy must also sell Ranbaxy’s generic minocycline capsule assets to Torrent, to enable Torrent to achieve regulatory approval for a change in ingredient suppliers for its minocycline tablets as quickly as Ranbaxy would have been able to do in the absence of the deal. In addition, Sun and Ranbaxy must supply generic minocycline tablets and capsules to Torrent until the company establishes its own manufacturing infrastructure.